AONC · American Oncology Network, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $470.28M | $433.98M | $364.34M | - | $336.31M | - | - | - | - |
| Cost of Revenue | - | $433.75M | $404.59M | $354.95M | - | $310.89M | - | - | - | - |
| Gross Profit | - | $36.53M | $29.39M | $9.39M | - | $25.41M | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | $34.74M | $23.91M | $28.28M | - | $25.20M | - | - | - | - |
| Total Operating Expenses | - | $468.68M | $318.63M | $383.58M | - | $291.23M | $1.50M | $1.01M | - | $969.2K |
| D&A | - | - | - | $2.51M | - | - | - | - | - | - |
| Operating Income | - | $1.60M | ($8.01M) | ($19.24M) | - | ($24.39M) | ($1.50M) | ($1.01M) | - | ($969.2K) |
| Interest Expense | - | $1.53M | $1.83M | $1.76M | - | $1.53M | - | - | - | - |
| Income Tax | - | $0 | ($324.0K) | $2.89M | - | $315.0K | $35.2K | $452.5K | - | $361.2K |
| Net Income | - | ($1.79M) | $3.29M | ($7.80M) | - | $0 | ($1.71M) | $179.4K | - | $3.41M |
| EPS - Basic | - | ($190.00) | $0.00 | ($1.22) | - | ($0.61) | - | - | - | - |
| EPS - Diluted | - | ($190.00) | ($110.00) | ($1.22) | - | ($0.61) | - | - | - | - |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.85M | $19.43M | $33.82M | $74.94M | $28.54M | $51.65M | $2.0K | $4.0K | $374.3K | $231.2K |
| Accounts Receivable | $129.23M | $128.01M | $125.42M | $132.30M | $129.15M | $136.10M | - | - | - | - |
| Inventory | $60.71M | $49.27M | $54.28M | $44.29M | $44.57M | $36.48M | - | - | - | - |
| Accounts Payable | $170.74M | $155.49M | $189.48M | $188.33M | $127.64M | $106.50M | - | - | - | - |
| Current Assets | $331.47M | $271.23M | $306.26M | $323.96M | $277.80M | $298.39M | $93.9K | $173.9K | $460.9K | $442.9K |
| Total Assets | $470.33M | $394.81M | $430.76M | $421.92M | $374.45M | $394.01M | $19.40M | $19.21M | $338.88M | $335.97M |
| Current Liabilities | $216.85M | $199.86M | $231.56M | $233.83M | $169.04M | $167.90M | $8.64M | $7.14M | $2.61M | $1.87M |
| Long-term Debt | $87.12M | $87.63M | $88.24M | $80.86M | $80.64M | $80.30M | - | - | - | - |
| Total Liabilities | $362.32M | $340.72M | $376.91M | $365.81M | $303.74M | $300.92M | $10.89M | $20.25M | $15.73M | $14.56M |
| Stockholders' Equity | ($46.22M) | ($103.83M) | ($39.98M) | ($167.45M) | ($161.73M) | ($341.33M) | ($10.17M) | ($19.66M) | ($14.20M) | ($13.51M) |
| Retained Earnings | ($102.17M) | ($103.49M) | ($66.72M) | ($175.59M) | ($161.81M) | ($341.36M) | ($21.37M) | ($19.66M) | ($14.20M) | ($13.51M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $45.14M | - | - | - | ($1.00M) | - | - |
| Investing Cash Flow | - | - | - | $1.52M | - | - | - | $321.59M | - | - |
| Financing Cash Flow | - | - | - | ($254.0K) | - | - | - | ($320.96M) | - | - |
| CapEx | - | - | - | $4.13M | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | $41.01M | - | - | - | - | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 7.8% | 6.8% | 2.6% | - | 7.6% | - | - | - | - |
| Operating margin | - | 0.3% | -1.8% | -5.3% | - | -7.3% | - | - | - | - |
| EBITDA margin | - | - | - | -4.6% | - | - | - | - | - | - |
| Net margin | - | -0.4% | 0.8% | -2.1% | - | 0.0% | - | - | - | - |
| Free cash flow margin | - | - | - | 11.3% | - | - | - | - | - | - |
| FCF / Net income | - | - | - | -5.26 | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | 7.4% | 5.5% | 7.8% | - | 7.5% | - | - | - | - |
| Effective tax rate | - | - | -10.9% | - | - | 100.0% | - | 71.6% | - | 9.6% |
| Return on assets | - | -0.5% | 0.8% | -1.8% | - | 0.0% | -8.8% | 0.9% | - | 1.0% |
| Return on equity | - | 1.7% | -8.2% | 4.7% | - | 0.0% | 16.8% | -0.9% | - | -25.2% |
| Return on invested capital | - | - | -16.6% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.53 | 1.36 | 1.32 | 1.39 | 1.64 | 1.78 | 0.01 | 0.02 | 0.18 | 0.24 |
| Quick ratio | 1.25 | 1.11 | 1.09 | 1.20 | 1.38 | 1.56 | 0.01 | 0.02 | 0.18 | 0.24 |
| Cash ratio | 0.29 | 0.10 | 0.15 | 0.32 | 0.17 | 0.31 | 0.00 | 0.00 | 0.14 | 0.12 |
| Leverage | ||||||||||
| Debt / Equity | -1.89 | -0.84 | -2.21 | -0.48 | -0.50 | -0.24 | - | - | - | - |
| Debt / Assets | 0.19 | 0.22 | 0.20 | 0.19 | 0.22 | 0.20 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | 1.0x | -4.4x | -10.9x | - | -15.9x | - | - | - | - |
| Equity multiplier | -10.18 | -3.80 | -10.77 | -2.52 | -2.32 | -1.15 | -1.91 | -0.98 | -23.86 | -24.86 |
| Liabilities / Assets | 0.77 | 0.86 | 0.87 | 0.87 | 0.81 | 0.76 | 0.56 | 1.05 | 0.05 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | - | 1.19 | 1.01 | 0.86 | - | 0.85 | - | - | - | - |
| Inventory turnover | - | 8.80 | 7.45 | 8.01 | - | 8.52 | - | - | - | - |
| Days sales outstanding | - | 99d | 105d | 133d | - | 148d | - | - | - | - |
| Days inventory outstanding | - | 41d | 49d | 46d | - | 43d | - | - | - | - |
| Days payable outstanding | - | 131d | 171d | 194d | - | 125d | - | - | - | - |
| Cash conversion cycle | - | 10d | -16d | -16d | - | 66d | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | 0.1x | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 39.8% | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 43.8% | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -434.9% | -1797.3% | - | -2416.7% | -433.1% | -305.1% | - | -144.2% |
| Net income growth (YoY) | - | - | - | - | - | - | - | -94.9% | - | 4.6% |
| EPS growth (YoY) | - | -31047.5% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 71.4% | 69.6% | -293.2% | -751.8% | -1038.6% | -2425.8% | 34.7% | -13.3% | 32.0% | 33.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$2.95B totalPatient Service$1.74B · 59.1%
Patient Visits$1.19B · 40.4%
Product And Service Other$15.51M · 0.5%
Peer comparison
Same SIC group: Services-Health Services
Comparing American Oncology Network against the 5 most active filers in the same SIC group.